Testing LQ036 inhaler for poorly controlled asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new inhaled medication called LQ036 to see if it can help people whose asthma is not well controlled with their current inhalers. Participants must have had at least one severe asthma flare-up in the last year and show signs of airway inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 to 75 years old with a body mass index (BMI) between 18 and 30.
- You have had asthma for at least 1 year and use daily inhaled steroids plus another control medicine.
- Your asthma is not well controlled—your score on a symptom questionnaire is 1.5 or higher, and your lung function is between 40% and 80% of normal.
- You must have had a positive response to a rescue inhaler (reversibility test) in the last 2 years or at screening.
- You have either a high level of eosinophils (150 or more) in your blood or a high exhaled nitric oxide level (25 ppb or more) at screening.
- You have had at least 1 severe asthma attack in the past year that required oral steroids or an emergency room visit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination inhaler (QVM149) against a standard one (Advair) in teenagers with asthma that isn't well controlled by their current medicine. It aims to see if the new inhaler works better.
This study tests a new medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with their current inhalers. It is for adults who have had asthma for at least a year, have had recent flare-ups needing steroids, and are not taking other biologic treatments.
This study tests an investigational drug to see if it can improve asthma control in people whose asthma is not well managed with current treatments. It may help reduce symptoms and improve lung function.
This study is testing whether an investigational drug called GSK5784283 can improve asthma control compared to a placebo. It is for people with uncontrolled asthma who are already on standard daily asthma medications.
This Phase 3 study compares a new inhaler (QMF149: indacaterol plus mometasone) against budesonide to see which works better and is safe for children ages 6 to under 12 with asthma. You may be able to join if your child is already on a stable low-dose steroid inhaler and still has symptoms.
This trial tests whether stepping up to either a higher dose of inhaled steroid/long-acting bronchodilator or a special fine-particle triple therapy (which includes an extra medication) can improve small-airway health in people whose asthma is still not well controlled on a medium-dose combination.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.